Phoenix Financial Ltd. increased its position in shares of BrainsWay Ltd. (NASDAQ:BWAY - Free Report) by 100.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 482,724 shares of the company's stock after buying an additional 242,366 shares during the period. Phoenix Financial Ltd. owned 2.56% of BrainsWay worth $4,552,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in BWAY. ARK Investment Management LLC bought a new position in shares of BrainsWay in the 4th quarter valued at about $1,656,000. JPMorgan Chase & Co. grew its position in BrainsWay by 61.9% during the 4th quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company's stock worth $226,000 after acquiring an additional 9,149 shares during the last quarter. Rhumbline Advisers grew its holdings in BrainsWay by 10.8% during the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock worth $207,000 after acquiring an additional 2,144 shares during the period. Finally, Sei Investments Co. bought a new position in shares of BrainsWay in the 4th quarter worth $149,000. 30.11% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of BrainsWay in a research report on Wednesday, March 12th.
Read Our Latest Report on BWAY
BrainsWay Stock Up 2.8 %
Shares of BWAY stock traded up $0.23 on Wednesday, hitting $8.58. The stock had a trading volume of 1,036 shares, compared to its average volume of 72,472. The company has a market cap of $161.90 million, a PE ratio of 85.81 and a beta of 1.17. The business has a 50 day moving average price of $9.75 and a 200 day moving average price of $9.82. BrainsWay Ltd. has a one year low of $4.61 and a one year high of $11.79.
BrainsWay Profile
(
Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Further Reading
Before you consider BrainsWay, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.
While BrainsWay currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
